<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="188">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104413</url>
  </required_header>
  <id_info>
    <org_study_id>M15-991</org_study_id>
    <secondary_id>2016-003190-17</secondary_id>
    <nct_id>NCT03104413</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus
      placebo during induction therapy in subjects with moderately to severely active CD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 24, 2017</start_date>
  <completion_date type="Anticipated">June 17, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 24, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with clinical remission per average daily stool frequency (SF) and average daily abdominal pain (AP) score at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical remission per average daily SF and average daily AP score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with endoscopic response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Endoscopic response defined as decrease from Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with enhanced clinical response at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Enhanced clinical response defined as decrease in average daily SF and/or decrease in average daily AP score, and/or clinical remission per average daily SF and average daily AP score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinical remission per Crohn's Disease Activity Index (CDAI) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The CDAI is used to evaluate disease activity in patients with Crohn's disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with enhanced clinical response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Enhanced clinical response defined as decrease in average daily SF and/or decrease in average daily AP score, and/or clinical remission per average daily SF and average daily AP score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinical remission per average daily stool frequency (SF) and average daily abdominal pain (AP) score at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Clinical remission per average daily SF and average daily AP score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with enhanced clinical response and endoscopic response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Enhanced clinical response defined as decrease in average daily SF and/or decrease in average daily AP score, and/or clinical remission per average daily SF and average daily AP score. Endoscopic response defined as decrease from Baseline in SES-CD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with endoscopic healing at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Endoscopic healing was assessed using SES-CD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crohn's Symptom Severity (CSS): Change from Baseline to Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The CSS is a patient questionnaire to assess severity of Crohn's symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with resolution of Extra-Intestinal Manifestations (EIMs) at Week 12, in participants with EIMs at Baseline</measure>
    <time_frame>Week 12</time_frame>
    <description>Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with hospitalization through Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants with an event that results in admission to the hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with draining fistulas at Week 12 in participants with draining fistulas at Baseline</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants with draining fistulas at Week 12 in subjects who had draining fistulas at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue): Change from Baseline to Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities over the past week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short Form Health Survey (SF-36): Change from Baseline to Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The SF-36 is an indicator of overall health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Crohn's Disease-related surgeries through Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants who underwent surgery related to CD.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">579</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo (Induction Period 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to receive placebo for risankizumab in Induction Period 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risankizumab Dose 1 (Induction Period 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to receive risankizumab dose 1 in Induction Period 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risankizumab Dose 2 (Induction Period 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to receive risankizumab dose 2 in Induction Period 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risankizumab Dose 1 (Induction Period 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risankizumab Dose 2 (Induction Period 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risankizumab dose 3 (Induction period 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risankizumab IV</intervention_name>
    <description>risankizumab administered as intravenous (IV) infusion.</description>
    <arm_group_label>Risankizumab Dose 1 (Induction Period 1)</arm_group_label>
    <arm_group_label>Risankizumab Dose 2 (Induction Period 1)</arm_group_label>
    <arm_group_label>Risankizumab Dose 1 (Induction Period 2)</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>BI 655066</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for risankizumab IV</intervention_name>
    <description>placebo for risankizumab administered as intravenous (IV) infusion.</description>
    <arm_group_label>Placebo (Induction Period 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risankizumab SC</intervention_name>
    <description>risankizumab administered by subcutaneous (SC) injection</description>
    <arm_group_label>Risankizumab Dose 2 (Induction Period 2)</arm_group_label>
    <arm_group_label>Risankizumab dose 3 (Induction period 2)</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>BI 655066</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged &gt;=18 to &lt;= 80 years at the Baseline Visit. Where locally
             permissible, subjects 16 to &lt; 18 years of age who meet the definition of Tanner stage
             5 for development at the Baseline Visit

          -  Diagnosis of CD for at least 3 months prior to Baseline

          -  Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF),
             abdominal pain (AP) score, and Simple Endoscopic Score for Crohn's Disease (SES-CD)

          -  Demonstrated intolerance or inadequate response to biologic therapy for CD

          -  If female, subject must meet the contraception recommendations

        Exclusion Criteria:

          -  Subject with a current diagnosis of ulcerative colitis or indeterminate colitis

          -  Subjects with unstable doses of concomitant Crohn's disease therapy

          -  Receipt of Crohn's disease approved biologic agents (within 8 weeks prior to
             Baseline), or any investigational biologic or other agent or procedure within
             minimally 35 days prior to the Baseline

          -  Prior exposure to p40 inhibitors (e.g., ustekinumab [Stelara]) or p19 inhibitors
             (e.g., risankizumab)

          -  Complications of Crohn's disease (strictures, stenosis, short bowel, etc)

          -  Having an ostomy or ileoanal pouch
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>April 4, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BI 655066</keyword>
  <keyword>ABBV-066</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
